MedWatch

Orphazyme to lead the way for more biotech IPOs

Last week, Orphazyme carried out the first IPO of a Danish biotech company in seven years. Now, the company has many expectations to meet, for instance, branding Denmark as an attractive country for biotech companies to go public.

Foto: Nasdaq/PR

“It felt a bit like a 100-meter race in the end of a marathon.”

This is CEO in Orphazyme Anders Hinsby’s comment to the run-up to the IPO that made his firm the first Danish biotech company going public on the Nasdaq Copenhagen Stock Exchange since 2010. Together with co-founder and Chief Scientific Officer Thomas Kirkegaard Jensen, he has held a series of roadshows to brand Orphazyme.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier